Page last updated: 2024-10-15

3'-fluoro-2',3'-dideoxyguanosine

Description

3'-fluoro-2',3'-dideoxyguanosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135431817
SCHEMBL ID914433
SCHEMBL ID15531667
MeSH IDM0155797

Synonyms (35)

Synonym
guanosine, 2',3'-dideoxy-3'-fluoro-
3'-fddg
miv-210 (*prodrug of flg*)
fddguo
92562-88-4
3'-fluoro-2',3'-dideoxyguanosine
gsk204937
2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one
2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one
2',3'-dideoxy-3'-fluoroguanosine
lagociclovir
lagociclovir [inn]
miv-210
uu109jju0u ,
unii-uu109jju0u
2',3'-dideoxy-3'-fluoro-guanosine
lagociclovir [who-dd]
2-amino-9-(2,3-dideoxy-3-fluoro-.beta.-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purin-6-on
3'-fluoro-2',3'-dideoxyguanosine;2-amino-9-((2s,4r,5s)-4-fluoro-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
2', 3'-dideoxy-3'-fluoroguanosine
2',3'- dideoxy-3'- fluoroguanosine
RTJUXLYUUDBAJN-KVQBGUIXSA-N
2',3'dideoxy-3'-fluoroguanosine
CS-3705
SCHEMBL914433
SCHEMBL15531667
AKOS025149452
HY-14844
DTXSID90239044
2-amino-9-((2r,4s,5r)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
2-amino-9-((2r,4s,5r)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6h-purin-6-one
Q27291270
2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1h-purin-6-one
AKOS040741933
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's2 (22.22)18.2507
2000's5 (55.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]